AbbVie Inc. Gain (Loss) on Disposition of Other Assets
AbbVie Inc. (ABBV) reported Gain (Loss) on Disposition of Other Assets of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfOtherAssets · last filed 2025-02-14
- AbbVie Inc. gain (loss) on disposition of other assets for the quarter ending 2022-12-31 was $0.00.
- AbbVie Inc. gain (loss) on disposition of other assets for the quarter ending 2022-09-30 was $0.00.
- AbbVie Inc. gain (loss) on disposition of other assets for the quarter ending 2021-12-31 was $0.00.
- AbbVie Inc. gain (loss) on disposition of other assets for the quarter ending 2021-09-30 was $0.00.
- AbbVie Inc. gain (loss) on disposition of other assets for fiscal 2024 was $0.00.
- AbbVie Inc. gain (loss) on disposition of other assets for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AbbVie Inc. gain (loss) on disposition of other assets for fiscal 2022 was $172.00M, a 152.94% increase from fiscal 2021.
- AbbVie Inc. gain (loss) on disposition of other assets for fiscal 2021 was $68.00M.
| Period end | Gain (Loss) on Disposition of Other Assets 3 month | Gain (Loss) on Disposition of Other Assets 6 month | Gain (Loss) on Disposition of Other Assets 9 month | Gain (Loss) on Disposition of Other Assets 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-14 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-14 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $0.00 derived: sum of 2 quarters · filed 2025-02-14 | $172.00M 10-K · filed 2025-02-14 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $172.00M 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $172.00M 10-Q · filed 2023-08-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $0.00 derived: sum of 2 quarters · filed 2024-02-20 | $68.00M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $68.00M 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | $68.00M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $0.00 derived: sum of 2 quarters · filed 2023-02-17 | $0.00 10-K · filed 2023-02-17 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-02 | |||
| 2019-12-31 | $330.00M 10-K · filed 2022-02-18 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-19 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |